Market Indices
Sector Heatmap
RGNX — REGENXBIO Inc.
NasdaqREGENXBIO Inc.
- O
- 7.50
- H
- 8.31
- L
- 7.44
- V
- 2.22M
RGNX — Latest News & Headlines
14 StoriesRGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold Stocktwits
REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Singapore
REGENXBIO Inc. (RGNX) stock price, news, quote and history Yahoo Finance Singapore
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
Regenxbio Stock Price Forecast. Should You Buy RGNX? StockInvest.us
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? Stocktwits
Mizuho Initiates Regenxbio (RGNX) Coverage with Outperform Ratin - GuruFocus
Mizuho Initiates Regenxbio (RGNX) Coverage with Outperform Ratin GuruFocus
(RGNX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
(RGNX) Price Dynamics and Execution-Aware Positioning Stock Traders Daily
Full Transcript: Regenxbio Q2 2026 Earnings Call - Benzinga
Full Transcript: Regenxbio Q2 2026 Earnings Call Benzinga
RGNX Apr 2027 19.000 call (RGNX270416C00019000) Stock Price, News, Quote & History - Yahoo! Finance Canada
RGNX Apr 2027 19.000 call (RGNX270416C00019000) Stock Price, News, Quote & History Yahoo! Finance Canada
RGNX Initiates Coverage On Mizuho -- Rating Set to Outperform - GuruFocus
RGNX Initiates Coverage On Mizuho -- Rating Set to Outperform GuruFocus
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? Stocktwits
REGENXBIO stock reports 60 percent three-year eye study response - AD HOC NEWS
REGENXBIO stock reports 60 percent three-year eye study response AD HOC NEWS
REGENXBIO stock reports durable gene therapy data from Phase II - AD HOC NEWS
REGENXBIO stock reports durable gene therapy data from Phase II AD HOC NEWS
RGNX Stock Rises Premarket: Mizuho Calls For Nearly 200% Upside On Gene Therapy Pipeline - Stocktwits
RGNX Stock Rises Premarket: Mizuho Calls For Nearly 200% Upside On Gene Therapy Pipeline Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy Stocktwits